Helix Biopharma Revenue

About Helix Biopharma

Helix Biopharma is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength with a diverse, clinical-stage pipeline of drug candidates with great potential and head start, honed into first-and best-in-class oncology medicines. Our pipeline’s driving force is a proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing cancers, including non-small cell lung cancer (NSCLC), pancreatic, colon and ovarian cancers. Its flagship candidate, Tumour Defence Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that modifies the microenvironment of common, hard-to-treat solid tumours, taking the brakes off the immune system’s anti-tumour defences and delivering a game-changing assist to today’s front-running anti-cancer therapies. Our pre-IND candidates include (i) an oral immune checkpoint modulator that aims to bring long-term remission within reach of patients relapsing with leukemia after allogeneic stem cell transplantation, and (ii) a pioneering oral gemcitabine chemotherapy geared to enrich the spectrum of disease-limiting and life-enhancing treatment outcomes for patients with prevalent, hard-to-treat cancers.

View contact profiles from Helix Biopharma